Cost–effectiveness of elagolix versus leuprolide acetate for treating moderate-to-severe endometriosis pain in the USA

Wang, Si-Tien; Johnson, Scott J.; Mitchell, Dominic; Soliman, Ahmed M.; Vora, Jamie; Agarwal, Sanjay

doi:10.2217/cer-2018-0124

Cited by 17 publications

(16 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In their 2018 assessment of elagolix, the Institute for Clinical and Economic Review (ICER) reported that ''use of elagolix to treat moderate-to-severe endometriosis-related pain provides clinical benefit in terms of gains in healthrelated quality of life relative to no active treatment.'' 53 In 2019, Wang et al 54 published a cost-effectiveness evaluation that indirectly compared elagolix with leuprolide acetate, described as one of the most commonly used second-line therapies for endometriosis. Both elagolix treatment regimens analyzed (150 mg once daily for 24 months and 200 mg twice daily for 6 months) were found to be more costeffective than leuprolide acetate (11.25 mg every 3 months for 12 months, with add-back norethindrone acetate during the latter 6 months).…”

Section: Managing Endometriosis As a Chronic Disease: Long-term Treatmentioning

confidence: 99%

A Clinician's Guide to the Treatment of Endometriosis with Elagolix

Leyland

Estes

Lessey³

et al. 2021

Journal of Women's Health

View full text Add to dashboard Cite

Pain associated with endometriosis is a considerable burden for women, permeating all aspects of their lives, from their ability to perform daily activities to their quality of life. Although there are many options for endometriosis-associated pain management, they are often limited by insufficient efficacy, inconvenient routes of administration, and/or intolerable side effects. Elagolix, a nonpeptide, small-molecule gonadotropinreleasing hormone (GnRH) receptor antagonist, is the first new oral therapy to be approved for the treatment of endometriosis-associated pain in the United States in more than a decade. Modulation of estradiol with elagolix is dose dependent and ranges from partial to full suppression. Clinical evidence has shown that elagolix at both approved doses (150 mg once daily and 200 mg twice daily) is effective for reducing symptoms of pelvic pain (dysmenorrhea, nonmenstrual pelvic pain, and dyspareunia), improving quality of life, and decreasing use of rescue analgesics (nonsteroidal anti-inflammatory drugs and/or opioids). The availability of two dosing options allows for individualization of treatment based on baseline clinical factors and response to therapy. Elagolix is well tolerated, with less pronounced hypoestrogenic effects compared with GnRH agonists. This review provides an overview of elagolix, highlighting currently available treatment options and the application of this new treatment for women with endometriosis-associated pain.

show abstract

Section: Managing Endometriosis As a Chronic Disease: Long-term Treatmentioning

confidence: 99%

A Clinician's Guide to the Treatment of Endometriosis with Elagolix

Leyland

Estes

Lessey³

et al. 2021

Journal of Women's Health

View full text Add to dashboard Cite

show abstract

“…Over 2 years, both doses were also associated with a positive NMB relative to leuprolide acetate (US$2374 and US$1342, respectively). 44 The results were robust to sensitivity analyses. 42 Mean hours gained in household productivity, defined as −1 × LS mean change from baseline in hours of household productivity lost due to absenteeism, presenteeism and total hours lost (absenteeism + presenteeism).…”

Section: Effect Of Elagolix On Non-pain Outcomesmentioning

confidence: 90%

“…Over 2 years, both doses were also associated with a positive NMB relative to leuprolide acetate (US$2374 and US$1342, respectively). 44 The results were robust to sensitivity analyses.…”

Section: Introductionmentioning

confidence: 90%

“…41 In another study, a Markov model was developed using data from the EM-I and EM-II clinical trials to assess the cost-effectiveness of elagolix versus leuprolide acetate for the management of moderate to severe endometriosis pain over 1and 2-year time frames. 44 Both doses of elagolix were associated with a positive net monetary benefit (NMB; i.e. more quality-adjusted life years for less costs) relative to leuprolide acetate over both 1-and 2-year time frames.…”

Section: Effect Of Elagolix On Non-pain Outcomesmentioning

confidence: 96%

See 1 more Smart Citation

Elagolix in the treatment of endometriosis: impact beyond pain symptoms

Archer

Soliman

Agarwal

et al. 2020

Clin Med�Insights�Reprod�Health

View full text Add to dashboard Cite

While the most common symptom associated with endometriosis is pelvic pain, the systemic manifestations of the disease and the accompanying adverse psychological, emotional, social, familial, sexual, educational and workplace effects are increasingly recognized. Elagolix is an oral gonadotropin-releasing hormone receptor antagonist that is approved for the management of moderate to severe pain associated with endometriosis. However, the benefits of elagolix extend beyond reducing pain symptoms. This article reviews the non-pain systemic manifestations associated with endometriosis and summarizes the beneficial effects of elagolix on non-pain outcomes. This includes improvements in quality of life, reductions in fatigue and improvements in workplace and household productivity. These results indicate that elagolix provides non-pain benefits in women with endometriosis and improves outcomes that are clinically meaningful to patients.

show abstract

“…Another US study, and the third most read article of 2019, comes from Wang et al, who assessed the costeffectiveness of elagolix versus leuprolide acetate in women with moderate-to-severe endometriosis pain; a condition that has been estimated to affect between 4 and 10% of women in their reproductive years [9].…”

Section: Content Highlights Of 2019mentioning

confidence: 99%